Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update
28/11/2023 15:10
Nov 28 (Reuters) - DMK Pharmaceuticals Corp DMK.O :
* DMK PHARMACEUTICALS REGAINS FULL RIGHTS FROM US WORLDMEDS
FOR
SYMJEPI® AND PROVIDES CORPORATE UPDATE
* DMK PHARMACEUTICALS- REACQUIRING RIGHTS TO SYMJEPI
(EPINEPHRINE)
INJECTION 0.3 MG AND SYMJEPI (EPINEPHRINE) INJECTION 0.15MG
PRODUCTS FROM USWM
* DMK PHARMACEUTICALS CORP - NOW ACTIVELY SEEKING
OUT-LICENSE
OPPORTUNITIES FOR SYMJEPI IN US AND GLOBALLY, IN ADDITION TO
EXPLORING OTHER OPTIONS
Source text for Eikon: ID:nGNXxDKLj
Further company coverage: DMK.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update